Bo Ahrén

81 – 90 of 398

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/af6f8d38-a95b-47b6-9ec5-5f69aa8d0e59?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
…
8
9
10
11
…
40
next »

2015
Mark DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.
Malmgren, Siri ^LU and Ahrén, Bo ^LU (2015) In Diabetologia 58(5). p.1091-1099
- Contribution to journal › Article
Mark Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Are there not some surrogate indexes lost in this story? Reply to Bastard JP, Rabasa-Lhoret R, Laville M and Disse E [letter]
Otten, Julia ; Ahrén, Bo ^LU and Olsson, Tommy (2015) In Diabetologia 58(2). p.416-417
- Contribution to journal › Letter
Mark Incretin and islet hormone responses to meals of increasing size in healthy subjects.
Alsalim, Wathik ^LU ; Omar, Bilal ^LU ; Pacini, Giovanni ; Bizzotto, Roberto ; Mari, Andrea and Ahrén, Bo ^LU (2015) In Journal of Clinical Endocrinology and Metabolism 100(2). p.561-568
- Contribution to journal › Article
Mark High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial
Jakubowicz, Daniela ; Wainstein, Julio ; Ahrén, Bo ^LU ; Bar-Dayan, Yosefa ; Landau, Zohar ; Rabinovitz, Hadas R. and Froy, Oren (2015) In Diabetologia 58(5). p.912-919
- Contribution to journal › Article
Mark Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
Ahrén, Bo ^LU (2015) In Diabetologia 58(8). p.1740-1744
- Contribution to journal › Debate/Note/Editorial
2014
Mark HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin.
Ahrén, Bo ^LU ; Johnson, Susan L ; Stewart, Murray ; Cirkel, Deborah T ; Yang, Fred ; Perry, Caroline and Feinglos, Mark N (2014) In Diabetes Care 37(8). p.2141-2148
- Contribution to journal › Article
Mark Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors.
Omar, Bilal ^LU and Ahrén, Bo ^LU (2014) In Diabetes 63(7). p.2196-2202
- Contribution to journal › Article
Mark The mind and the belly: a glance at how the nervous system directs metabolism
Accili, D. ; Ahrén, Bo ^LU ; Boitard, C. ; Seino, S. ; Thorens, B. and Cerasi, E. (2014) In Diabetes, Obesity and Metabolism 16. p.1-3
- Contribution to journal › Debate/Note/Editorial
Mark Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial
Jakubowicz, Daniela ; Froy, Oren ; Ahrén, Bo ^LU ; Boaz, Mona ; Landau, Zohar ; Bar-Dayan, Yosefa ; Ganz, Tali ; Barnea, Maayan and Wainstein, Julio (2014) In Diabetologia 57(9). p.1807-1811
- Contribution to journal › Article
Mark Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.
Rosenstock, Julio ; Fonseca, Vivian A ; Gross, Jorge L ; Ratner, Robert E ; Ahrén, Bo ^LU ; Chow, Francis C C ; Yang, Fred ; Miller, Diane ; Johnson, Susan L and Stewart, Murray W , et al. (2014) In Diabetes Care 37(8). p.2317-2325
- Contribution to journal › Article

« previous
1
…
8
9
10
11
…
40
next »